首页> 美国卫生研究院文献>Bulletin of the World Health Organization >Vaccine adverse events in the new millennium: is there reason for concern?
【2h】

Vaccine adverse events in the new millennium: is there reason for concern?

机译:新千年的疫苗不良事件:是否值得关注?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

As more and more infectious agents become targets for immunization programmes, the spectrum of adverse events linked to vaccines has been widening. Although some of these links are tenuous, relatively little is known about the immunopathogenesis of even the best characterized vaccine-associated adverse events (VAAEs). The range of possible use of active immunization is rapidly expanding to include vaccines against infectious diseases that require cellular responses to provide protection (e.g. tuberculosis, herpes viral infections), therapeutic vaccines for chronic infections (e.g. human immunodeficiency virus (HIV) infection, viral hepatitis B and C), and vaccines against non-infectious conditions (e.g. cancer, autoimmune diseases). Less virulent pathogens (e.g. varicella, rotavirus in the developed world) are also beginning to be targeted, and vaccine use is being justified in terms of societal and parental "costs" rather than in straightforward morbidity and mortality costs. In the developed world the paediatric immunization schedule is becoming crowded, with pressure to administer increasing numbers of antigens simultaneously in ever simpler forms (e.g. subcomponent, peptide, and DNA vaccines). This trend, while attractive in many ways, brings hypothetical risks (e.g. genetic restriction, narrowed shield of protection, and loss of randomness), which will need to be evaluated and monitored. The available epidemiological and laboratory tools to address the issues outlined above are somewhat limited. As immunological and genetic tools improve in the years ahead, it is likely that we shall be able to explain the immunopathogenesis of many VAAEs and perhaps even anticipate and avoid some of them. However, this will only happen if the human and financial resources needed for monitoring and studying vaccine safety stay in step with the accelerating pace of vaccine development. Failure to make such a commitment would put all immunization programmes at risk.
机译:随着越来越多的传染剂成为免疫计划的目标,与疫苗相关的不良事件的范围正在扩大。尽管这些联系中的一些是微不足道的,但即使是最有特征的疫苗相关不良事件(VAAE)的免疫发病机制,也知之甚少。主动免疫的可能用途范围正在迅速扩大,包括针对需要细胞反应以提供保护的传染病疫苗(例如结核,疱疹病毒感染),用于慢性感染的治疗疫苗(例如人免疫缺陷病毒(HIV)感染,病毒性肝炎) B和C),以及针对非传染性疾病(例如癌症,自身免疫性疾病)的疫苗。毒性较低的病原体(例如发达国家的水痘,轮状病毒)也开始成为攻击目标,疫苗的使用正以社会和父母的“成本”为依据,而不是直接的发病率和死亡率成本。在发达国家,小儿免疫计划日趋拥挤,以越来越简单的形式同时施用越来越多的抗原(例如,亚成分,肽和DNA疫苗)的压力越来越大。这种趋势虽然在许多方面具有吸引力,但会带来假设风险(例如遗传限制,保护范围变窄以及失去随机性),需要对其进行评估和监控。用于解决上述问题的流行病学和实验室工具在一定程度上受到限制。随着未来几年免疫学和遗传学工具的发展,我们很有可能能够解释许多VAAE的免疫发病机理,甚至可以预期并避免其中的一些。但是,只有在监视和研究疫苗安全性所需的人力和财力与疫苗开发的步伐保持同步的情况下,才会发生这种情况。不作出这样的承诺将使所有免疫计划面临风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号